Uniplan Investment Counsel Inc. Makes New $475,000 Investment in Dynavax Technologies Corporation $DVAX

Key Points

• Uniplan Investment Counsel Inc. has acquired 36,585 shares of Dynavax Technologies, valued at approximately $475,000, as part of their new position in the company.
• Institutional investors own 96.96% of Dynavax Technologies' stock, with significant growth in holdings reported by firms like Invesco Ltd. and Walleye Capital LLC in the first quarter.
• Dynavax Technologies reported a quarterly earnings per share of $0.14, surpassing the consensus estimate of $0.12, alongside revenue of $95.44 million, exceeding analyst expectations.

Uniplan Investment Counsel Inc. purchased a new position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 36,585 shares of the biopharmaceutical company's stock, valued at approximately $475,000.

Other large investors also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale acquired a new position in shares of Dynavax Technologies during the 1st quarter worth about $30,000. Caitong International Asset Management Co. Ltd raised its holdings in Dynavax Technologies by 5,485.7% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 2,304 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Dynavax Technologies in the 4th quarter valued at approximately $35,000. GAMMA Investing LLC raised its holdings in Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after acquiring an additional 3,627 shares in the last quarter. Finally, Moloney Securities Asset Management LLC acquired a new position in Dynavax Technologies in the 1st quarter valued at approximately $131,000. Institutional investors own 96.96% of the company's stock.

Dynavax Technologies Price Performance

Shares of DVAX stock traded down $0.20 during trading on Wednesday, hitting $9.72. The company had a trading volume of 1,371,340 shares, compared to its average volume of 1,809,836. The stock's 50-day moving average price is $10.62 and its 200 day moving average price is $11.15. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. Dynavax Technologies Corporation has a one year low of $9.22 and a one year high of $14.63. The firm has a market capitalization of $1.14 billion, a P/E ratio of -21.13 and a beta of 1.24.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The company had revenue of $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. Equities analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Wall Street Zen raised Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. JMP Securities reiterated a "market outperform" rating and issued a $32.00 price objective on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Insider Activity

In related news, Director Scott Dunseth Myers bought 3,800 shares of the business's stock in a transaction on Friday, August 22nd. The stock was acquired at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the purchase, the director directly owned 35,004 shares in the company, valued at $378,743.28. This trade represents a 12.18% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.98% of the stock is currently owned by corporate insiders.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.